IDH1/2 mutants consume NADPH to produce D-2-HG, which similarly inhibits α-KG–dependent chromatin and DNA demethylases, driving a hypermethylation phenotype that can initiate tumorigenesis, particularly in gliomas and hematologic malignancies (55, 56). This evidence concerns the gene IDH1 and central nervous system cancer.